Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study)

被引：0
|
作者：
Motzer, Robert [1 ]
George, Saby [2 ]
Merchan, Jaime R. [3 ]
Hutson, Thomas E. [4 ,5 ]
Song, Xun [6 ]
Perini, Rodolfo F. [6 ]
Xie, Ran [7 ]
Bapat, Urmi [7 ]
Ebaid, Basant [8 ]
Puente, Javier [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[2] Roswell Park Comprehens Canc Ctr, Dept Med, Buffalo, NY USA
[3] Univ Miami, Dept Med, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Baylor Charles A Sammons Canc Ctr, Dept Med Oncol, Texas Oncol, Dallas, TX USA
[5] Texas A&M HSC Coll Med, Bryan, TX USA
[6] Merck & Co Inc, Rahway, NJ 07065 USA
[7] Eisai Inc, Nutley, NJ USA
[8] Eisai Australia Pty Ltd, Melbourne, Vic, Australia
[9] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
196
引用
收藏
页码：121 / 122
页数：2
相关论文
共 50 条
  • [21] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [22] New drug approval: Lenvatinib plus pembrolizumab for advanced renal cell carcinoma
    Saillant, Arnaud
    Borchiellini, Delphine
    BULLETIN DU CANCER, 2022, 109 (7-8) : 737 - +
  • [23] Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Mathew
    Stepan, Daniel E.
    Shumaker, Robert
    Schmidt, Emmett V.
    Guo, Matthew
    Dutcus, Corina
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 174 - 175
  • [24] Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma REPLY
    Motzer, Robert
    Choueiri, Toni K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03): : 287 - 287
  • [25] Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma
    Volkova, M., I
    Kalpinskiy, A. S.
    Goncharova, O. A.
    Menshikov, K. V.
    Stativko, O. A.
    Karabina, E. V.
    Dergunov, A. S.
    Polshina, N. I.
    Aleksandrova, E. N.
    Lebedinets, A. A.
    Panov, A. K.
    Sultanbaev, A. V.
    Usynin, E. A.
    Volkonsky, M. V.
    Mikhalyuk, V. V.
    Zukov, R. A.
    Anzhiganova, Yu. V.
    Gusniev, M. A.
    Igumnova, E. N.
    Kuzmicheva, S. V.
    Pokataev, I. A.
    Olshanskaya, A. S.
    Pervakova, N. I.
    Parsadanova, E. L.
    Sannikova, T. A.
    Bystrov, A. A.
    Dubovichenko, D. M.
    Mukhitova, M. R.
    Chubenko, V. A.
    Shkret, K. A.
    Gorshenina, M. N.
    Semenov, A. V.
    Davlatova, M. K.
    Kosareva, A. E.
    Lutoshkina, O. A.
    Maslova, O. A.
    Makhnutina, M. V.
    Mishina, A. V.
    Murzalina, M. Zh.
    Podyacheva, O. A.
    Kalinin, S. A.
    Mailyan, O. A.
    Safarova, A. R.
    Semenova, K. O.
    Strokova, M. A.
    Urashkina, E. Yu.
    Shmygina, O. S.
    Novikova, O. Yu.
    ONKOUROLOGIYA, 2024, 20 (03):
  • [26] Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC)
    Panian, Justine
    Zhong, Caiwei
    Choi, Sharon
    Quinn, Roxanne
    Ferrier, Evan
    Saad, Eddy
    Saliby, Renee Maria
    Malvar, Carmel
    Pal, Sumanta
    Ebrahimi, Hedyeh
    Tran, Ben
    Jude, Evon
    Lalani, Aly-Khan
    Suarez, Cristina
    De Velasco, Guillermo
    Kanesvaran, Ravindran
    Zarba, Martin
    Chehade, Razane El Hajj
    Choueiri, Toni K.
    Heng, Daniel
    McKay, Rana
    ONCOLOGIST, 2024, 29 : S23 - S23
  • [27] Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
    Grunwald, Viktor
    Powles, Thomas
    Choueiri, Toni K.
    Hutson, Thomas E.
    Porta, Camillo
    Eto, Masatoshi
    Sternberg, Cora N.
    Rha, Sun Young
    He, Cixin S.
    Dutcus, Corina E.
    Smith, Alan
    Dutta, Lea
    Mody, Kalgi
    Motzer, Robert J.
    FUTURE ONCOLOGY, 2019, 15 (09) : 929 - 941
  • [28] Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
    Rha, Sun Young
    Choueiri, Toni K.
    Matveev, Vsevolod B.
    Alyasova, Anna
    Hong, Sung-Hoo
    Gordoa, Teresa Alonso
    Gurney, Howard
    Bjarnason, Georg A.
    Buchler, Tomas
    Pedrazzoli, Paolo
    Takagi, Toshio
    Park, Se Hoon
    Lee, Jae-Lyun
    Perini, Rodolfo F.
    He, Cixin
    McKenzie, Jodi A.
    Eto, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [29] Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial
    Rha, Sun Young
    Choueiri, Toni K.
    Matveev, Vsevolod B.
    Alyasova, Anna
    Hong, Sung-Hoo
    Gordoa, Teresa Alonso
    Gurney, Howard
    Bjarnason, Georg A.
    Buchler, Tomas
    Pedrazzoli, Paolo
    Takagi, Toshio
    Park, Se Hoon
    Lee, Jae Lyun
    Perini, Rodolfo F.
    He, Cixin S. S.
    McKenzie, Jodi A.
    Eto, Masatoshi
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (06) : 1241 - 1250
  • [30] Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results.
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew W.
    Taylor, Matthew H.
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Schmidt, Emmett V.
    Guo, Matthew
    Dutcus, Corina E.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345